Ferric Derisomaltose

Ferric Derisomaltose is a scientifically advanced intravenous iron replacement therapy developed for the effective management of iron deficiency anemia. Unlike conventional iron salts, it is a carbohydrate-based iron (III) complex, offering high stability, safety, and excellent patient tolerability.

The formulation is colourless, odourless, and non-hygroscopic, eliminating metallic taste and moisture sensitivity commonly associated with traditional iron preparations.

As a leading API manufacturer, WBCIL follows strict cGMP and ISO quality systems, supported by manufacturing expertise since 1962, ensuring consistent potency, purity, and safety across every batch.

Key Therapeutic Advantages:

• High-dose iron delivery for rapid correction of iron deficiency
• Controlled iron release minimizing adverse reactions
• Fewer infusions compared to conventional IV iron therapies
• Improved patient compliance and clinical outcomes

WBCIL Product Highlights:

• Patent held by WBCIL on Ferric Derisomaltose
• Eminent scientific journals have published studies on WBCIL’s Ferric Derisomaltose
• Minimal hypersensitivity reactions reported
• Sameness study completed with the innovator product
• Compliant with Indian Pharmacopoeia (IP)

Applications in Medical Fields:

• Iron Deficiency Anemia Treatment
• Chronic Kidney Disease
• Rapid Iron Replenishment
• Postpartum Anemia
• Chronic Heart Failure
• Inflammatory Bowel Disease